December 21, 2017

Name: Alex Young, PharmD
Company/Organization: Pharmacyclics LLC, an AbbVie Company
Address: 995 East Arques Avenue, Sunnyvale, CA 94085
Phone: 408.215.3412
E-mail: alyoung@pcyc.com
Date of request: December 21, 2017
NCCN Guidelines® Panel: B-Cell Lymphomas

Dear NCCN:

Pharmacyclics LLC and Janssen Biotech, Inc. co-develop and co-commercialize IMBRUVICA® (ibrutinib) capsules. On behalf of Pharmacyclics LLC and Janssen Biotech, Inc., I respectfully request the NCCN Guidelines® - B-Cell Lymphomas Panel to review the enclosed information of IMBRUVICA (ibrutinib) for the treatment of mantle cell lymphoma (MCL).

Specific Change: Consider the available data on IMBRUVICA in patients with MCL for your updating purposes.

FDA Clearance:
IMBRUVICA® is a kinase inhibitor indicated for the treatment of adult patients with:
- Mantle cell lymphoma (MCL) who have received at least one prior therapy. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
- Waldenström’s macroglobulinemia (WM)
- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy

Rationale: Conference proceedings from the 59th Annual Meeting of the American Society of Hematology (ASH) have reported on a updated pooled analysis of ibrutinib as a single-agent in patients with relapsed/refractory (R/R) MCL.
- Rule et al (2017)\(^2,3\) presented updated results (median follow-up of 41.1 months) of a pooled analysis of baseline factors on response rates and survival outcomes in ibrutinib-treated patients with R/R MCL from international, open-label, phase 2, phase 3, and phase 3b studies (N=370) (PCYC-1104, MCL2001 [SPARK], MCL3001 [RAY], and CAN3001). Previously published results were described with median follow-up of 24 months from Rule et al (2016).\(^4\)

The following references are submitted with the full prescribing information\(^1\) in support of the proposed change. We would like to acknowledge the contributions of the NCCN panel members who are also co-authors or co-contributors of these publications.


Sincerely,

Alex Young, PharmD
Manager, Scientific Communications
Pharmacyclics LLC, an AbbVie Company